- $499.19m
- $470.91m
- $320.17m
AngioDynamics Q1 sales beat on med tech segment growth
AngioDynamics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
AngioDynamics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
AngioDynamics Inc reports results for the quarter ended May 31 - Earnings Summary
AngioDynamics Q4 sales beat estimates on Med Tech strength
AngioDynamics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: AngioDynamics Says Palmetto GBA finalizes Medicare Nanoknife coverage from July 5, 2026
Brief: Angiodynamics Announces Two-Year Preserve Trial Data Demonstrating Durable Nanoknife Ire System Outcomes In Intermediate-Risk Prostate Cancer
Brief: Angiodynamics Files Patent Infringement Lawsuit Against Endovascular Engineering On April 23, 2026
AngioDynamics Q3 revenue beats estimates on Med Tech strength, raises outlook
U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla
U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin
U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge
U.S. STOCKS ON THE MOVE-Intel, Vistra, Jackson Financial
Angiodynamics up after annual sales forecast raise
Medical devices maker AngioDynamics raises FY sales, adjusted EBITDA guidance
U.S. RESEARCH ROUNDUP- Grail, Maplebear, Ocular Therapeutix
Angiodynamics rises after raising FY sales forecast
Medical devices maker AngioDynamics Q1 net sales beats estimates, raises annual rev guidance